Monoclonal gammopathy of undetermined significance and anti-TNF-α treatment [3]

Scandinavian Journal of Rheumatology

Volumn 36, Issue 5, 2007, Pages 405-406

  Smale, S W ^a   Lawson, T M ^a  

^a PRINCESS OF WALES HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BENCE JONES PROTEIN; ETANERCEPT; IMMUNOGLOBULIN LAMBDA CHAIN; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; PARAPROTEIN; PREDNISOLONE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

DRUG EFFECT; DRUG RESPONSE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HUMAN; INCIDENCE; LETTER; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; RISK;

AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; HUMANS; MALE; MULTIPLE MYELOMA; PARAPROTEINEMIAS; PRECANCEROUS CONDITIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35648947966     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.1080/03009740701286904     Document Type: Letter

References (6)

1. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance: a review. Immunol Rev 2003;194:112-39.
2. Garton MJ, Keir G, Dickie A, Steven M, Rennie JAN. Prevalence and long-term significance of paraproteinaemia in rheumatoid arthritis. Rheumatology 2006;45:355-6.
3. Tsimberidou A-M, Waddelow T, Kantarjian HM, Albitar M, Giles F. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNFα levels during treatment. Leuk Res 2003;27:375-80.
4. Kast RE. Evidence for a mechanism by which etanercept increased TNF-alpha in multiple myeloma: new insights into the biology of TNF-alpha giving new treatment opportunities: the role of bupropion. Leuk Res 2005;29:1459-63.
5. Ledingham J, Deighton C; British Society for Rheumatology Standards, Guidelines and Audit Working Group. Update onthe British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidance of April 2001). Rheumatology 2005;44:157-63.
6. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twentyfour weeks. Arthritis Rheum 2006;54:2793-806.